Preventive HIV vaccines

Progress and challenges

Ayoko R. Bossou, Shana Castillo, Karen K. O’Brien, Catherine A. Opere, Christopher J. Destache

Research output: Contribution to specialist publicationArticle

Abstract

Infection with HIV, which is the cause of AIDS, is a major public-health concern throughout the world, especially in developing countries. Once a person is infected with HIV, he or she remains infected for life, even with treatment. Despite the success of standard regimens, antiretroviral therapy is complicated by potential drug-drug interactions, patient nonadherence, and adverse effects. Therefore, developing a safe, effective vaccine that prevents HIV infection is the best strategy for containing the epidemic. Despite progress in vaccine development, there is still no effective vaccine for preventing HIV. Because HIV is highly diverse, it integrates into the host genome and develops ways to evade the immune system. Many roadblocks persist in the field of HIV vaccine development.

Original languageEnglish
Pages46-50
Number of pages5
Volume40
No10
Specialist publicationU.S. Pharmacist
StatePublished - Oct 16 2015

Fingerprint

AIDS Vaccines
HIV Infections
Vaccines
HIV
Patient Compliance
Drug Interactions
Drug interactions
Developing Countries
Immune System
Acquired Immunodeficiency Syndrome
Public Health
Immune system
Genome
Public health
Developing countries
Genes
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this

Bossou, A. R., Castillo, S., O’Brien, K. K., Opere, C. A., & Destache, C. J. (2015). Preventive HIV vaccines: Progress and challenges. U.S. Pharmacist, 40(10), 46-50.

Preventive HIV vaccines : Progress and challenges. / Bossou, Ayoko R.; Castillo, Shana; O’Brien, Karen K.; Opere, Catherine A.; Destache, Christopher J.

In: U.S. Pharmacist, Vol. 40, No. 10, 16.10.2015, p. 46-50.

Research output: Contribution to specialist publicationArticle

Bossou, AR, Castillo, S, O’Brien, KK, Opere, CA & Destache, CJ 2015, 'Preventive HIV vaccines: Progress and challenges' U.S. Pharmacist, vol. 40, no. 10, pp. 46-50.
Bossou AR, Castillo S, O’Brien KK, Opere CA, Destache CJ. Preventive HIV vaccines: Progress and challenges. U.S. Pharmacist. 2015 Oct 16;40(10):46-50.
Bossou, Ayoko R. ; Castillo, Shana ; O’Brien, Karen K. ; Opere, Catherine A. ; Destache, Christopher J. / Preventive HIV vaccines : Progress and challenges. In: U.S. Pharmacist. 2015 ; Vol. 40, No. 10. pp. 46-50.
@misc{0f5df3bc3ffe46f580556e061f950ef7,
title = "Preventive HIV vaccines: Progress and challenges",
abstract = "Infection with HIV, which is the cause of AIDS, is a major public-health concern throughout the world, especially in developing countries. Once a person is infected with HIV, he or she remains infected for life, even with treatment. Despite the success of standard regimens, antiretroviral therapy is complicated by potential drug-drug interactions, patient nonadherence, and adverse effects. Therefore, developing a safe, effective vaccine that prevents HIV infection is the best strategy for containing the epidemic. Despite progress in vaccine development, there is still no effective vaccine for preventing HIV. Because HIV is highly diverse, it integrates into the host genome and develops ways to evade the immune system. Many roadblocks persist in the field of HIV vaccine development.",
author = "Bossou, {Ayoko R.} and Shana Castillo and O’Brien, {Karen K.} and Opere, {Catherine A.} and Destache, {Christopher J.}",
year = "2015",
month = "10",
day = "16",
language = "English",
volume = "40",
pages = "46--50",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Preventive HIV vaccines

T2 - Progress and challenges

AU - Bossou, Ayoko R.

AU - Castillo, Shana

AU - O’Brien, Karen K.

AU - Opere, Catherine A.

AU - Destache, Christopher J.

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Infection with HIV, which is the cause of AIDS, is a major public-health concern throughout the world, especially in developing countries. Once a person is infected with HIV, he or she remains infected for life, even with treatment. Despite the success of standard regimens, antiretroviral therapy is complicated by potential drug-drug interactions, patient nonadherence, and adverse effects. Therefore, developing a safe, effective vaccine that prevents HIV infection is the best strategy for containing the epidemic. Despite progress in vaccine development, there is still no effective vaccine for preventing HIV. Because HIV is highly diverse, it integrates into the host genome and develops ways to evade the immune system. Many roadblocks persist in the field of HIV vaccine development.

AB - Infection with HIV, which is the cause of AIDS, is a major public-health concern throughout the world, especially in developing countries. Once a person is infected with HIV, he or she remains infected for life, even with treatment. Despite the success of standard regimens, antiretroviral therapy is complicated by potential drug-drug interactions, patient nonadherence, and adverse effects. Therefore, developing a safe, effective vaccine that prevents HIV infection is the best strategy for containing the epidemic. Despite progress in vaccine development, there is still no effective vaccine for preventing HIV. Because HIV is highly diverse, it integrates into the host genome and develops ways to evade the immune system. Many roadblocks persist in the field of HIV vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=84944474836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944474836&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 46

EP - 50

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -